They found degradation of Bcl-XL resulted in apoptosis of Tregs and activation of CD8+ T-cells, noting that small-molecule PROTACs for Bcl-XL can be promising adjuvant agents in tumor immunotherapy [68,150]. The gene discussed is BCL2L1; the disease is neoplasm.